[go: up one dir, main page]

AU5256301A - Froindazole derivative - Google Patents

Froindazole derivative

Info

Publication number
AU5256301A
AU5256301A AU52563/01A AU5256301A AU5256301A AU 5256301 A AU5256301 A AU 5256301A AU 52563/01 A AU52563/01 A AU 52563/01A AU 5256301 A AU5256301 A AU 5256301A AU 5256301 A AU5256301 A AU 5256301A
Authority
AU
Australia
Prior art keywords
froindazole
derivative
froindazole derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU52563/01A
Inventor
Seiki Goto
Kyoichi Maeno
Akio Miyafuji
Atsushi Nakamura
Itsurou Shimada
Takumi Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of AU5256301A publication Critical patent/AU5256301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU52563/01A 2000-04-28 2001-04-25 Froindazole derivative Abandoned AU5256301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-129854 2000-04-28
JP2000129854 2000-04-28
PCT/JP2001/003556 WO2001083487A1 (en) 2000-04-28 2001-04-25 Froindazole derivative

Publications (1)

Publication Number Publication Date
AU5256301A true AU5256301A (en) 2001-11-12

Family

ID=18639062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52563/01A Abandoned AU5256301A (en) 2000-04-28 2001-04-25 Froindazole derivative

Country Status (2)

Country Link
AU (1) AU5256301A (en)
WO (1) WO2001083487A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305732B2 (en) * 2001-06-01 2007-02-01 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057213A2 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
CL2004000826A1 (en) 2003-04-25 2005-03-04 Pfizer USE OF AN AGONIST FOR THE 5-HT2C RECEPTOR TO PREPARE A USEFUL MEDICINAL PRODUCT IN THE TREATMENT OF URINARY INCONTINENCE CAUSED BY STRESS, WITH THE CONDITION THAT THE AGONIST IS NOT 1- [6-CHLORINE-5- (TRIFLUOROMETIL) -2- PIRIDINIL] PIPERAZINA (ORG-129
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US6989445B2 (en) 2003-12-15 2006-01-24 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2011071136A1 (en) 2009-12-11 2011-06-16 アステラス製薬株式会社 Therapeutic agent for fibromyalgia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
MX2022007685A (en) 2019-12-19 2022-07-19 Bayer Ag Furoindazole derivatives.
CA3211437A1 (en) 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
WO2022229061A1 (en) 2021-04-29 2022-11-03 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880867A (en) * 1974-02-05 1975-04-29 Squibb & Sons Inc Derivatives of furo(2,3-d)pyrazolo(3,4-b)pyridines
TW270114B (en) * 1993-10-22 1996-02-11 Hoffmann La Roche
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305732B2 (en) * 2001-06-01 2007-02-01 Alcon, Inc. Pyranoindazoles and their use for the treatment of glaucoma

Also Published As

Publication number Publication date
WO2001083487A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU5256301A (en) Froindazole derivative
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001293852A1 (en) Sulfonylguanidine
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001254731A1 (en) Substituted phenyluracils
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2001234313A1 (en) Novel phenylheteroalkylamine derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2001246864A1 (en) Hypotensors
AU2002221632A1 (en) 5-amino-1-pentene-3-ol substituted derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase